119 related articles for article (PubMed ID: 9726054)
1. Massive lymphocytic infiltration of uterine leiomyomas associated with GnRH agonist treatment.
Bardsley V; Cooper P; Peat DS
Histopathology; 1998 Jul; 33(1):80-2. PubMed ID: 9726054
[TBL] [Abstract][Full Text] [Related]
2. Unusual morphologic features of uterine leiomyomas treated with gonadotropin-releasing hormone agonists: massive lymphoid infiltration and vasculitis.
McClean G; McCluggage WG
Int J Surg Pathol; 2003 Oct; 11(4):339-44. PubMed ID: 14615835
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyomas with T-cell infiltration associated with GnRH agonist goserelin.
Laforga JB; Aranda FI
Histopathology; 1999 May; 34(5):471-2. PubMed ID: 10231516
[No Abstract] [Full Text] [Related]
4. Morphological changes in uterine leiomyomas treated by GnRH agonist goserelin.
Crow J; Gardner RL; McSweeney G; Shaw RW
Int J Gynecol Pathol; 1995 Jul; 14(3):235-42. PubMed ID: 8600075
[TBL] [Abstract][Full Text] [Related]
5. Uterine leiomyoma with massive lymphoid infiltration: case report and review of the literature.
Paik SS; Oh YH; Jang KS; Han HX; Cho SH
Pathol Int; 2004 May; 54(5):343-8. PubMed ID: 15086839
[TBL] [Abstract][Full Text] [Related]
6. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
Colgan TJ; Pendergast S; LeBlanc M
Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
[TBL] [Abstract][Full Text] [Related]
7. Cellular leiomyoma mimicking endometrial stromal neoplasm in association with GnRH agonist goserelin.
McCluggage WG; Bharucha H
Histopathology; 1999 Feb; 34(2):184-6. PubMed ID: 10064405
[No Abstract] [Full Text] [Related]
8. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
[TBL] [Abstract][Full Text] [Related]
9. GnRH analogues and uterine leiomyomas. Effect of hormone replacement therapy on cell proliferation.
Rintala S; Kujansuu E; Teisala K; Rantala I; Kivinen S; Tuimala R
Gynecol Obstet Invest; 1999; 48(4):276-9. PubMed ID: 10592433
[TBL] [Abstract][Full Text] [Related]
10. Frequency, histological, and immunohistochemical properties of massive inflammatory lymphocytic infiltration of leiomyomas of the uterus: an entity causing diagnostic difficulties.
Botsis D; Koliopoulos C; Kondi-Pafitis A; Creatsas G
Int J Gynecol Pathol; 2005 Oct; 24(4):326-9. PubMed ID: 16175076
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of a case of uterine leiomyoma showing massive lymphoid infiltration and localized vasculitis after LH-RH derivant treatment.
Ohmori T; Wakamoto R; Lu LM; Okada K; Nose M
Histopathology; 2002 Sep; 41(3):276-7. PubMed ID: 12207795
[No Abstract] [Full Text] [Related]
12. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
13. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
14. Uterine Leiomyoma with Massive Lymphoid Infiltrate in a Patient with History of Assisted In-Vitro Fertilization.
Prete MD; Collamarini M; Collamarini C; Sesti F; Mauriello A; Palmieri G
Turk Patoloji Derg; 2020; 36(3):251-255. PubMed ID: 31960941
[TBL] [Abstract][Full Text] [Related]
15. Uterine leiomyoma with indolent B-lymphoblastic proliferation.
Wang Z; Sun K; Xiao W
Int J Clin Exp Pathol; 2013; 6(7):1422-6. PubMed ID: 23826425
[TBL] [Abstract][Full Text] [Related]
16. Genic expression of the uterine leiomyoma in reproductive-aged women after treatment with goserelin.
Borsari R; Bozzini N; Junqueira CR; Soares JM; Hilário SG; Baracat EC
Fertil Steril; 2010 Aug; 94(3):1072-7. PubMed ID: 19481745
[TBL] [Abstract][Full Text] [Related]
17. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
18. Effects of treatment with gonadotropin releasing hormone agonist on the uterine leiomyomata structure.
Bozzini N; Rodrigues CJ; Petti DA; Bevilacqua RG; Gonçalves SP; Pinotti JA
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):330-4. PubMed ID: 12716317
[TBL] [Abstract][Full Text] [Related]
19. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
20. Pathological evaluation of uterine leiomyomas treated with gonadotropin-releasing hormone agonist (GnRH-a) therapy: role of mast cells and a possible mechanism of GnRH-a resistance in leiomyomas.
Nakayama M; Mitsuhashi T; Shimizu Y; Ishihara O; Shimizu M
Pathol Int; 2008 May; 58(5):268-74. PubMed ID: 18429824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
